SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of results from the Pediatric Artificial ...
An artificial pancreas developed at the University of Virginia Center for Diabetes Technology improves blood sugar control for people ages 2 to 72 with type 1 diabetes, according to a new combined ...
Control-IQ technology is intended for use with a compatible integrated continuous glucose monitor (iCGM, sold separately) and ACE pump to automatically increase, decrease, and suspend delivery of ...
Abbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S. Tandem’s Control-IQ™ hybrid closed-loop technology now ...
Tandem Diabetes Care, Inc. TNDM recently commercially launched Control-IQ+ technology - the latest generation of its advanced hybrid closed-loop algorithm in the United States. Control-IQ+ is ...
A new study evaluated the effect of hybrid-closed loop Control-IQ technology in the pooled data from three randomized controlled trials, comparing Control-IQ to a control group using continuous ...
Continuous glucose monitors and other connected technologies for diabetes management have traditionally been used overwhelmingly by people with Type 1 diabetes, though major devicemakers like Dexcom ...
Tandem Diabetes Care TNDM remained under pressure on Monday, after the company accounted for plans of a combined analysis of three trials of its Control-IQ technology. Tandem Diabetes Care’s margins ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results